Necessity of using intermediate outcome to proxy long term effects. The example of thrombolytics.
Schwartz
J S
JS
Department of Medicine, University of Pennsylvania, Philadelphia, USA.
D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D015233:Models, Statistical; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000191:economics; D017063:Outcome Assessment, Health Care; D010043:Outcome and Process Assessment, Health Care; D016896:Treatment Outcome